^
Association details:
| Biomarker: | TRIM33-BRAF fusion |
|---|---|
| Cancer: | Melanoma |
| Drug: | Ojemda (tovorafenib) (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical Activity of the Type II Pan-RAF Inhibitor Tovorafenib in BRAF-Fusion Melanoma
Published date:
04/20/2023
Excerpt:
Patient 2 is a 35-year-old white male with a TRIM33-BRAF fusion malignant melanoma, and progressed after treatment with radiation…He had a partial response (PR) at the 8-week scan on tovorafenib, which was confirmed at 16 weeks...Early results from the first three patients of this ongoing trial showed tovorafenib is generally well tolerated and has encouraging antitumor activity in BRAF-fusion melanoma.
